Soligenix, Inc. (NASDAQ:SNGX) shares are trending on Wednesday.
SNGX shares surged 72.32% to $0.88 in after-hours trading Tuesday following the biotech’s announcement that its ThermoVax platform can rapidly develop a Bundibugyo virus vaccine, addressing a World Health Organization-declared Ebola outbreak emergency.
Something went wrong.
Soligenix made this announcement on Tuesday addressing an urgent outbreak declared a Public Health Emergency of International Concern.
Critical Vaccine Gap Drives Catalyst
